An adjunctive medication used in combination with carbidopa-levodopa therapy for patients with severe parkinson’s disease. Tolcapone inhibits the metabolism of levodopa by catechol-omethyltransferase (COMT), allowing greater levels of levodopa to penetrate the brain, where it can be converted to dopamine. Marketed under the brand name tasmar.